News
Click here for news in Danish.
August 03, 2022 | Company Announcements
Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023 July 22, 2022 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox July 19, 2022 | Company Announcements
Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023 July 18, 2022 | Company Announcements
Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox OutbreakJuly 15, 2022 | Company Announcements
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic July 01, 2022 | Company Announcements
U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic June 14, 2022 | Company Announcements
Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak June 10, 2022 | Company Announcements
Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government June 07, 2022 | Company Announcements
Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of CanadaMay 30, 2022 | Company Announcements
Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox OutbreakMay 25, 2022 | Company Announcements
Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox OutbreakMay 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMay 18, 2022 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 18, 2022 | Company Announcements
Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government May 09, 2022 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2022May 05, 2022 | Company Announcements
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine CandidateApril 29, 2022 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchApril 24, 2022 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such April 20, 2022 | Company Announcements
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults April 05, 2022 | Company Announcements
Resolutions of the Annual General Meeting 2022 of Bavarian Nordic A/SMarch 21, 2022 | Company Announcements
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian MarketsMarch 18, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMarch 14, 2022 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting March 04, 2022 | Company Announcements
Bavarian Nordic Publishes Annual Report 2021